Viatris price target raised to $10 from $9 at BofA

BofA raised the firm’s price target on Viatris to $10 from $9 and keeps an Underperform rating on the shares, citing a sector re-rating. The firm, which forecasts Q4 sales and EBITDA roughly in-line with consensus, says its multiple for Viatris reflects a lack of growth and track record of accretive business development.